% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Merz:129236,
      author       = {M. Merz and T. Hielscher$^*$ and A. Seckinger and D. Hose
                      and E. K. Mai and M.-S. Raab$^*$ and H. Goldschmidt$^*$ and
                      A. Jauch and J. Hillengass$^*$},
      title        = {{B}aseline characteristics, chromosomal alterations, and
                      treatment affecting prognosis of deletion 17p in newly
                      diagnosed myeloma.},
      journal      = {American journal of hematology},
      volume       = {91},
      number       = {11},
      issn         = {0361-8609},
      address      = {New York, NY},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2017-05241},
      pages        = {E473 - E477},
      year         = {2016},
      abstract     = {Deletion 17p13, del(17p), is associated with poor outcome
                      in myeloma but some patients show long-term survival. With
                      the current study we intended to identify factors impacting
                      outcome of such high risk patients. We analyzed 110 newly
                      diagnosed, symptomatic patients with del(17p) detected by
                      fluorescence in situ hybridization (FISH) in CD138-purified
                      myeloma cells to identify prognostic factors for survival.
                      Age >65 years, ISS III, and elevated LDH negatively impacted
                      survival. Patients with subclonal $(10-60\%$ of plasma
                      cells) del(17p) had longer progression-free survival (PFS)
                      than patients with del(17p) in $>60\%$ of plasma cells (26
                      vs. 19 months, P = 0.03). Additional gain of 1q21 was
                      associated with shorter PFS (17 vs. 25 months,
                      P = 0.01). Hyperdiploidy did not ameliorate impact of
                      del(17p), but gain 19q13 predicted longer PFS (30 vs. 18
                      months, P = 0.01) and overall survival (50 vs. 29
                      months, P = 0.01). Multivariate analysis in transplant
                      eligible patients (≤65 years) revealed better survival for
                      patients treated with upfront autologous transplantation
                      (hazard ratio, $[95\%$ confidence interval]: 0.15 [0.04,
                      0.58], P = 0.006). Application of maintenance therapy
                      was associated with better survival in transplant-eligible
                      patients (0.30 [0.09, 0.99], P = 0.05). We demonstrate
                      heterogeneous outcome of patients with del(17p) according to
                      baseline characteristics and treatment. 19q13 should be
                      included in routine FISH panel, since gains were associated
                      with better survival. Am. J. Hematol. 91:E473-E477, 2016. ©
                      2016 Wiley Periodicals, Inc.},
      cin          = {C060 / G170 / G330 / V964 / E010},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331 / I:(DE-He78)G170-20160331 /
                      I:(DE-He78)G330-20160331 / I:(DE-He78)V964-20160331 /
                      I:(DE-He78)E010-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27508939},
      doi          = {10.1002/ajh.24533},
      url          = {https://inrepo02.dkfz.de/record/129236},
}